Treats pain of osteoarthritis of the knee(s). ANDA 208021, held by Lupin Pharms. Diclofenac Sodium.
As of Nov 16, 2026, ANDA 208021 (Diclofenac Sodium), held by Lupin Pharms, was first approved by FDA on Sep 21, 2022, with 1 approved supplement and 0 published complete response letters.
Diclofenac sodium topical solution is a nonsteroidal anti-inflammatory drug indicated for the treatment of the pain of osteoarthritis of the knee(s).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 21, 2022 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Diclofenac Sodium2% · solution;topical | Diclofenac Sodium | Rx |
| Nov 21, 2024 | Supplement 4Labeling · Standard review | Approved | None posted |
| Sep 21, 2022 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters